Published in Anticancer Res on August 28, 2008
Case Report: Extreme Levels of Serum S-100B in a Patient with Chronic Subdural Hematoma. Front Neurol (2012) 1.53
Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clin Transl Med (2016) 0.75
A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien) (2016) 0.75
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res (1988) 3.91
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature (2001) 3.57
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med (1987) 3.04
BRAF(E600) in benign and malignant human tumours. Oncogene (2007) 2.45
Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31
How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29
Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol (1997) 2.28
Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene (1992) 2.22
Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene (2001) 2.21
[Guideline 'Melanoma' (3rd revision)]. Ned Tijdschr Geneeskd (2005) 2.08
Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008. Br J Dermatol (2012) 2.03
Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J (2009) 2.01
Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg (2001) 1.79
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. Eur J Surg Oncol (2008) 1.69
Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest (1994) 1.69
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst (1991) 1.64
Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol (2005) 1.52
Lymph node metastasis from melanoma with an unknown primary site. Br J Surg (1990) 1.49
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer (2010) 1.49
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer (1991) 1.47
High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg (2004) 1.46
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol (2002) 1.46
Functional 'immaturity' of isolated B cells from patients with hypogammaglobulinaemia. Clin Exp Immunol (1980) 1.45
Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg (2007) 1.43
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
Finding lymph node metastases in invasive breast cancer: sampling or sentinel node procedure? Eur J Surg Oncol (2002) 1.39
[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35
Diagnosis of thin melanoma. J Clin Pathol (1997) 1.28
Two immunologically distinct forms of late-onset hypogammaglobulinaemia. Clin Exp Immunol (1981) 1.27
Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol (1977) 1.26
Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med (2000) 1.25
MR imaging of clear cell sarcoma (malignant melanoma of the soft parts): a multicenter correlative MRI-pathology study of 21 cases and literature review. Skeletal Radiol (2000) 1.21
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
Detection of unknown occult primary tumors using positron emission tomography. Cancer (1998) 1.18
Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg (2000) 1.13
Cytomegalovirus-directed lymphocyte reactivity in healthy adults tested by a CMV-induced lymphocyte transformation test. Clin Exp Immunol (1977) 1.10
The hidden sentinel node in breast cancer. Eur J Nucl Med Mol Imaging (2002) 1.10
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer (2002) 1.10
Alveolar soft part sarcoma. a report of 15 cases. Eur J Cancer (2002) 1.08
The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation. Clin Exp Immunol (1985) 1.07
Small cell melanoma. J Clin Pathol (2001) 1.06
Functional studies on T cells in adult human bone marrow. Clin Exp Immunol (1979) 1.05
Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene (1988) 1.05
History of sentinel node and validation of the technique. Breast Cancer Res (2001) 1.05
Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol (2001) 1.04
Amiodarone pneumonitis: three further cases with a review of published reports. Thorax (1984) 1.04
Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol (2000) 1.04
Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2002) 1.04
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol (1997) 1.03
Keratin subtypes in carcinomas of the uterine cervix: implications for histogenesis and differential diagnosis. Cancer Res (1990) 1.01
Classification of congenital melanocytic naevi and malignant transformation: a review of the literature. Br J Plast Surg (2004) 1.01
Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer (1998) 1.01
An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol (2006) 1.00
The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol (1989) 1.00
Comparison of four different assays for determination of serum S-100B. Int J Biol Markers (2005) 1.00
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol (1992) 0.99
Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer (1995) 0.98
Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol (2000) 0.98
The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol (2007) 0.98
Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis. Histopathology (2001) 0.97
Suppression of DNA synthesis by Con A-activated human lymphocytes: Stimulation by con A bound to non-T cells unless removed after activation. Clin Exp Immunol (1977) 0.97
Vascular complications of isolated limb perfusion. Eur J Surg Oncol (1998) 0.97
Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol (2000) 0.96
Gastroesophageal reflux and Barrett's esophagus in adults born with esophageal atresia. Am J Gastroenterol (1999) 0.96
Sentinel node biopsy for melanoma in the head and neck region. Head Neck (2000) 0.96
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung? Epidemiology (2001) 0.94
Lymphatic mapping and sentinel node biopsy in Merkel's cell carcinoma. Eur J Surg Oncol (2006) 0.94
Monoclonal antibody 123C3, identifying small cell carcinoma phenotype in lung tumours, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues. Int J Cancer Suppl (1988) 0.94
The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer (1998) 0.94
Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension. Thorax (1999) 0.94
Ultrastructure of the liver in th cerebrohepatorenal syndrome of Zellweger. Ultrastruct Pathol (1984) 0.93
The illusion of the learning phase for lymphatic mapping. Ann Surg Oncol (2002) 0.93
Sentinel nodes outside lymph node basins in patients with melanoma. Br J Surg (2001) 0.93
Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res (1995) 0.93
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer (2003) 0.92